Clinical trial
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for…
NCT00037206 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00037206 |
|---|---|
| Title | A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). |
| Official title | An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Vicuron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Aspergillosis |
| Intervention type | Drug |
| Interventions | Anidulafungin, VER002 |
| Enrollment | 30 |
| Start date | May 1, 2002 |
| Completion | Feb 1, 2003 |
| First posted | May 17, 2002 |
| Last update posted | Oct 21, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: